恩格列净与2型糖尿病患者视网膜病变风险
该研究基于美国商业保险和Medicare数据库(2014年8月至2019年9月),采用新使用者活性对照队列设计,比较2型糖尿病患者启动恩格列净 vs 二肽基肽酶4抑制剂(DPP4i)后非增殖性糖尿病视网膜病变(NPDR)发生和糖尿病视网膜病变(DR)进展的风险。结果发现,恩格列净与NPDR发生风险无关(HR 1.04;95%CI 0.94-1.15),但可能与DR进展风险较低相关(HR 0.78;95%CI 0.63-0.96)。
要点
- 恩格列净 vs DPP4i的NPDR发生风险无显著差异(HR 1.04;95%CI 0.94-1.15)。
- 恩格列净组DR进展风险低于DPP4i组(HR 0.78;95%CI 0.63-0.96)。
- 恩格列净可能与DR进展风险较低相关,但观察性设计无法完全排除残余混杂。
核心结论
- 与启动DPP4i相比,启动恩格列净与NPDR发生风险无关,但可能与DR进展风险较低相关。
- 由于研究的观察性性质,不能完全排除残余混杂,这些发现可能有助于权衡成人2型糖尿病患者不同降糖药物的风险与获益。
研究设计与样本
- 采用新使用者活性对照队列研究设计,使用美国2家商业保险公司和Medicare的全国保险索赔数据,时间范围为2014年8月至2019年9月。
- 纳入启动研究药物的成人2型糖尿病患者,且无增殖性DR或其他晚期视网膜疾病诊断或治疗史;评估NPDR发生结局时额外排除有NPDR病史者,评估DR进展结局时要求有NPDR病史。
- NPDR发生队列倾向评分匹配后共34 239对,DR进展队列匹配后共7 831对;NPDR队列中35 867例(52.4%)为男性,平均(SD)年龄65.6(10.3)岁;DR进展队列中8 229例(52.5%)为男性,平均(SD)年龄67.0(10.0)岁。
- 数据分析时间为2022年8月至2024年5月。
主要发现
- 在平均(SD)随访8(7.5)个月的治疗期间,NPDR发生风险在恩格列净组与DPP4i组间无差异(HR 1.04;95%CI 0.94-1.15;RD 1.30;95%CI -1.83至4.44)。
- DR进展风险在启动恩格列净者中低于启动DPP4i者(HR 0.78;95%CI 0.63-0.96;RD -9.44;95%CI -16.90至-1.98)。
- 结果在多个亚组和敏感性分析中一致。
关键数值与推荐
- NPDR发生定义为轻度、中度或重度NPDR的诊断代码。
- DR进展结局定义为新发增殖性DR、玻璃体出血、启动玻璃体腔内抗血管内皮生长因子注射或全视网膜光凝的复合终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 由于研究的观察性性质,不能完全排除残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Empagliflozin might lower the risk of diabetic retinopathy (DR) by preventing retinal pericyte loss. However, the role of empagliflozin with respect to DR in patients with type 2 diabetes (T2D) remains unclear. OBJECTIVE: To compare the risk of incident nonproliferative DR (NPDR) and DR progression in patients with T2D initiating empagliflozin vs a dipeptidyl peptidase 4 inhibitor (DPP4i). DESIGN, SETTING, AND PARTICIPANTS: A new-user active-comparator cohort study was conducted using US nationwide insurance claims data from 2 commercial insurers and Medicare from August 2014 to September 2019. Adults with T2D initiating study drugs without prior diagnosis or treatment for proliferative DR or other advanced retinal diseases were included. To assess incident NPDR, patients with a history of NPDR were additionally excluded, while for the DR progression outcome, patients were required to have a history of NPDR. Data were analyzed from August 2022 to May 2024. EXPOSURES: Initiation of empagliflozin or a DPP4i. MAIN OUTCOMES AND MEASURES: Incident NPDR was defined using diagnostic codes for mild, moderate, or severe NPDR. The DR progression outcome was defined as a composite of incident proliferative DR, vitreous hemorrhage, initiation of intravitreal anti-vascular endothelial growth factor injection, or panretinal photocoagulation. Incidence rates, hazard ratios (HRs), and rate differences (RDs) with 95% CIs were estimated. RESULTS: A total of 34 239 pairs of propensity-score matched adults were identified in the incident NPDR cohort and 7831 pairs in the DR progression cohort. In the incident NPDR cohort, 35 867 patients (52.4%) were male, and the mean (SD) age was 65.6 (10.3) years. In the DR progression cohort, 8229 patients (52.5%) were male, and the mean (SD) age was 67.0 (10.0) years. Over a mean (SD) follow-up period of 8 (7.5) months receiving treatment, the risk of incident NPDR was not different across groups (HR, 1.04; 95% CI, 0.94 to 1.15; RD, 1.30; 95% CI, -1.83 to 4.44), while the risk of DR progression was lower among individuals who initiated empagliflozin compared with those who began DPP4i therapy (HR, 0.78; 95% CI, 0.63 to 0.96; RD, -9.44; 95% CI, -16.90 to -1.98). Results were consistent across multiple subgroups and sensitivity analyses. CONCLUSIONS AND RELEVANCE: Compared with initiation of a DPP4i, empagliflozin initiation was not associated with incident NPDR, although it may be associated with a lower risk of DR progression. Although residual confounding cannot be entirely ruled out due to the observational nature of our study, these findings may be helpful when weighing the risks and benefits of various glucose-lowering agents in adults with T2D.
引用
- Tesfaye H, Paik JM, Roh M, et al. Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes. JAMA Ophthalmol. 2025. PMID: 39636645. doi:10.1001/jamaophthalmol.2024.5219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。